This is the first long-term follow-up of a clinical trial assessing an additive treatment for stomach cancer consisting of a fully human IgM antibody directed specifically against the tumour-specific CD55PAT-SC1 variant of CD55. This evidence concerns the gene CD40LG and neoplasm.